NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

I kinda forgot I wrote this, and I’m not as old as Trump/Biden.

Still, it seems this stands up when I read what I mostly forgot I wrote.🙃

flipper44
Member Level
Re: None
Tuesday, 04/30/2024 4:57:06 PM

So I’m not certain people realize what’s going on. A few once promising immune approaches
are dropping by the wayside. Gilead’s program, using an antibody targeting a protein (cd47) on both healthy cells (whoops) and cancer cells was discontinued in blood cancers and all solid tumor cancers. Additionally, Standard Car-T therapy against proteins (bcma and cd19) expressed by healthy cells and blood/lymph B cell cancers received a black box (April 18, 224) warning because it can cause multiple other cancers and/or stay in the body, as transgenes, causing other mutations for decades.

Similarly, Infiltrating lymphocyte therapy, which first uses chemotherapy to destroy the immune system cells, was halted a few months ago and restarted due to grade 5 adverse reactions.

Also, Company after company going after one or a limited subset of cancer antigens are not able to avoid tumor escape. Most of them readily admit this.

The new head of engineering and manufacturing at Advent is not most recently from Roche, he is from Autolous (six years) a Car-T company hit hard by the scientific outcome of Car-T therapy. Through no fault of his own, the Car-T therapy industry is dealing with very serious safety issues.

All of the strategies employed by big pharma above knew going into it that they were risking either safety, tumor escape or both, but economics, intellectual property and/or other hurdles pushed them into questionable or outright poor and very expensive risks/decisions.